ArticleBiological trace element research2026
Montelukast Ameliorates Antimony-Induced Neurotoxicity Accompanied by Alterations in Oxidative Stress, Neuroinflammation, and Mitochondrial Function.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimony (Sb) is a metalloid widely used in industry, especially in the manufacture of polyethylene terephthalate (PET), commonly used to make water bottles, food packaging, and other consumer products. Recently, Sb has been identified as a novel nerve toxin, which elicits neuronal death and associated neurodegeneration. Montelukast, a cysteinyl leukotriene receptor antagonist, has demonstrated neuroprotective effects in various experimental models of neurodegenerative disorders. This study was designed to explore the neuroprotective effect of montelukast against Sb-induced neurotoxicity. Thirty Swiss albino mice were randomly allocated into five different groups: control, montelukast (M) per se, Sb-10 mg/kg, Sb + M1 (Sb 10 mg/kg + montelukast 5 mg/kg), and Sb + M2 (Sb 10 mg/kg + montelukast 10 mg/kg) groups. Spatial memory, oxidative stress (lipid peroxides, reduced glutathione), cholinergic function (acetylcholinesterase), neuroinflammatory parameters (myeloperoxidase, tumour necrosis factor-α, interleukins-6 and 10), mitochondrial enzyme activities (I, II, IV), neurotrophin (BDNF and CREB), and histopathological alterations were assessed. Sb exposure significantly impaired cognitive performance, which was associated with increased oxidative stress (↑ lipid peroxides and ↓ glutathione), cholinergic dysfunction (↓ acetylcholinesterase), neuroinflammation (↑ myeloperoxidase, ↑ IL-6, and ↑ TNF-α and ↓ IL-10), disturbed mitochondrial enzyme functions (↓ complex I, II, and IV), reduced neurotrophin levels (↓ BDNF and ↓ CREB), and neuronal damage. Montelukast significantly (p ≤ 0.05) attenuated these alterations and improved behavioural function compared with the Sb-treated group. The findings suggest that montelukast can reduce Sb-induced neurotoxic alterations in mice, likely through regulating oxidative stress, neuroinflammatory responses, and mitochondrial enzyme dysfunction. However, these findings are derived from a preclinical mouse model. Further mechanistic studies and clinical trials are required to validate these findings and evaluate their translational implications.
Indexed as
Identifiers
42658428What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.